🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. Precision Cells

    Ningbo Cancer Hospital

    Precision Cell Immunotherapy

    phase 2 mab active

    1 trial

  2. RITUXIMAB, Golcadomide

    Fondazione Telethon ETS

    Diffuse Large B-cells non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  3. Rabipur Polvere e solvente per soluzione iniettabile in siringa preriempita. Vaccino rabico (inattivato)., TICOVAC 0,25 ml per uso pediatrico Sospensione iniettabile in una siringa preriempita Vaccino (virus intero, inattivato) contro l'encefalite da zecca, AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4+ T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomye

    Fondazione Telethon ETS

    X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)

    phase 2 small molecule active

    1 trial

  4. Rixathon 100 mg concentrate for solution for infusion, Aplo-TCSE TCRaß+CD19+ depleto, Allogeneic peripheral blood-derived NK cells CD3- CD56+, Qarziba 4.5 mg/mL concentrate for solution for infusion, Melfalan Tillomed 50 mg polvere e solvente per soluzione iniettabile/infusione, TEPADINA 100 mg powder for concentrate for solution for infusion, Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione, Grafalon 20 mg/ml concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  5. Stem cells

    Takeda

    Rheumatoid Arthritis Aggravated

    phase 2 gene therapy completed

    1 trial

  6. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  7. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial

  8. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  9. Temozolomide

    The First People's Hospital of Lianyungang

    Cytokine-Induced Killer Cells

    phase 2 small molecule active

    1 trial

  10. Umbilical Cord Mesenchymal Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injuries

    phase 2 small molecule active

    2 trials

  11. Umbilical Cord Mesenchymal Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injury

    phase 2 small molecule active

    1 trial

  12. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  13. allogeneic human mesenchymal stem cells (hMSCs)

    United Therapeutics Europe Ltd

    Non-ischemic Dilated Cardiomyopathy

    phase 2 mab active

    1 trial

  14. anti-CD133-CAR vector-transduced T cells

    Chinese PLA General Hospital

    Liver Cancer

    phase 2 mab completed

    1 trial

  15. anti-CD7 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  16. anti-MUC1 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  17. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  18. autologous dendritic cells pulsed with tumor lysate antigen Vaccine

    NORTHWEST BIOTHERAPEUTICS INC

    Giant Cell Glioblastoma

    phase 2 mab terminated

    1 trial

  19. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial

  20. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial

  21. pCAR-19B cells

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  22. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  23. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial

  24. umbilical cord blood (hUCB) cells

    S.L

    Cerebral Palsy

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources